Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.
Riihimaki M, Thomsen H, Brandt A, et al. Death causes in breast cancer patients. Ann Oncol. 202;23:604–610. https://doi.org/10.1093/annonc/mdr160
Chapman JA, Meng D, Shepherd L, et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst. 2008;100:252–60.
Bradshaw PT, Stevens J, Khankari N, et al. Cardiovascular disease mortality among breast cancer survivors. Epidemiology. 2016;27:6–13. https://doi.org/10.1097/EDE.0000000000000394
Gernaat SAM, Ho PJ, Rijnberg N, et al. Risk of death from cardiovascular disease following breast cancer: a systematic review. Breast Cancer Res Treat. 2017;164(3):537–55. https://doi.org/10.1007/s10549-017-4282-9.
Article CAS PubMed PubMed Central Google Scholar
Patnaik JL, Byers T, DiGuiseppi C, et al. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011;13:R64. https://doi.org/10.1186/bcr2901.
Article PubMed PubMed Central Google Scholar
Kolodziejczyk C, Jakobsen M, Jensen MS, Poulsen PB, Khan H, Kümler T, Andersson M. Mortality from cardiovascular disease in women with breast cancer – a nationwide registry study. Acta Oncol. 2021;60(10):1257–63. https://doi.org/10.1080/0284186X.2021.1959054.
Weaver KE, Foraker RE, Alfano CM, et al. Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care? J Cancer Surviv. 2013;7:253–61. https://doi.org/10.1007/s11764-013-0267-9.
Article PubMed PubMed Central Google Scholar
Macacu A, Autier P, Boniol M, et al. Active and passive smoking and risk of breast cancer: a meta-analysis. Breast Cancer Res Treat. 2015;154:213–24.
Bagnardi V, RotaM, Botteri E, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer. 2015;112:580–593.
Zhou Y, Zhao H, Peng C. Association of sedentary behavior with the risk of breast cancer in women: update meta-analysis of observational studies. Ann Epidemiol. 2015;25:687–97.
Abdel-Qadir H, Thavendiranathan P, Austin PC, et al. The risk of heart failure and other cardiovascular hospitalizations after early stage breast cancer: a matched cohort study. J Natl Cancer Inst. 2019;111:854–62.
Article PubMed PubMed Central Google Scholar
Boekel NB, Schaapveld M, Gietema JA, et al. Cardiovascular disease risk in a large, population-based cohort of breast cancer survivors. Int J Radiat Oncol Biol Phys. 2016;94:1061–72.
• Matthews AA, Peacock Hinton S, et al. Risk of Cardiovascular Diseases Among Older Breast Cancer Survivors in the United States: A Matched Cohort Study. J Natl Compr Canc Netw. 2021; 5:1–10. https://doi.org/10.6004/jnccn.2020.7629. The results of this study highlight the importance of identifying racial disparities in adverse cardiovascular outcomes. As breast cancer diagnosis was associated with an increased risk of coronary artery disease and myocardial infarction in Black women but a decreased risk of these in White women.
Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA: A Cancer J Clin. 2016;66:309–25.
Narayan HK, Finkelman B, French B, et al. Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up. Circulation. 2017;135:1397–412. https://doi.org/10.1161/CIRCULATIONAHA.116.023463.
Article PubMed PubMed Central Google Scholar
Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34:1102–11. https://doi.org/10.1093/eurheartj/ehs181.
Article CAS PubMed Google Scholar
Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26:1231–8. https://doi.org/10.1200/JCO.2007.13.5467.
Article CAS PubMed Google Scholar
Semiglazov VFSV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in post-menopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110:244–54.
Article CAS PubMed Google Scholar
Goldhirsch A, Glick J, Gelber RD. International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16(10):1569–83.
Article CAS PubMed Google Scholar
Albain KS, Barlow WE, Ravdin PM, et al. A randomized trial of adjuvant chemotherapy and tamoxifen timing inpostmenopausal, endocrine-responsive, node-positive breast cancer. Lancet. 2009;374(9707):2055–63.
Article PubMed PubMed Central Google Scholar
Mendelsohn ME. Protective effects of estrogen on the cardiovascular system. Am J Cardiol. 2002;89(12A):12E-E17.
Article CAS PubMed Google Scholar
Prat A, Cheang MC, Martín M, et al. Prognostic significance of progesterone receptor–positive tumor cells within immunohistochemically defined luminal a breast cancer. J Clin Oncol. 2013;10(31):203–9.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer:report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371–88.
Article CAS PubMed Google Scholar
Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;6(1):67–75.
Vogel VG, Costantino JP, Wickerham DL, et al. Effects of Tamoxifen vs Raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;296(24):2926.
Controlled trial of Tamoxifen as a single adjuvant agent in the management of early breast cancer. ‘Nolvadex’ Adjuvant Trial Organisation. Br J Cancer. 1988;57(6):608
Dunn, Barbara K et al. JNCI and cancer prevention. J Nat Cancer Inst. https://doi.org/10.1093/jnci/djv021.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717.
Peccatori FA, Azim HA Jr, Orecchia R et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi160–vi170.
Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2019;37(5):423–38. https://doi.org/10.1200/JCO.18.01160.
Article CAS PubMed Google Scholar
Baum M, Buzdar A, Cuzick J, et al. Anastrazole alone or in combination with Tamoxifen ver- sus Tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98(9):1802–10.
Article CAS PubMed Google Scholar
Lambertini M, Goldrat O, Clatot F, et al. Controversies about fertility and pregnancy issues in young breast cancer patients: Current state of the art. Curr Opin Oncol. 2017;29:243–52.
LHRH-agonists in Early Breast Cancer Overview group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369(9574):1711–23. https://doi.org/10.1016/S0140-6736(07)60778-8.
Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372:923–32.
Article CAS PubMed PubMed Central Google Scholar
Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial. Diabetologia. 2004;47(7):1175–87.
Article CAS PubMed Google Scholar
Sahebkar A, Serban MC, Penson P, et al. The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis. Drugs. 2017;77(11):1187–97.
Article CAS PubMed PubMed Central Google Scholar
McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ. 1995;311:977–980.
Rutqvist LE, Mattsson A, for the Stockholm Breast Cancer Study Group. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993;85(17):1398–406.
Rutqvist LE, Johansson H. Stockholm Breast Cancer Group. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol. 2007;46:133–145.
Reis SE, Costantino JP, Wickerham DL, et al. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst. 2001;93(1):16–21. https://doi.org/10.1093/jnci/93.1.16.
Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352:98–101.
Article CAS PubMed Google Scholar
Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 2007;99:727–37.
Article CAS PubMed Google Scholar
Josefsson ML, Leinster SJ. Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post- menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy. Breast. 2010;19(2):76e83.
Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17):1299e309.
Bushnell CD, Goldstein LB. Risk of ischemic stroke with tamoxifen treatment for breast cancer. Neurology. 2004;63(7):1230–3. https://doi.org/10.1212/01.WNL.0000140491.54664.50.
Article CAS PubMed Google Scholar
Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18(11):937–47. https://doi.org/10.1046/j.1525-1497.2003.20724.x.
Article PubMed PubMed Central Google Scholar
Fernández-Suárez ME, Daimiel L, Villa-Turégano G, Pavón MV, Busto R, Escolà-Gil JC, Platt FM, Lasunción MA, Martínez-Botas J, Gómez-Coronado D. Selective estrogen receptor modulators (SERMs) affect cholesterol homeostasis through the master regulators SREBP and LXR. Biomed Pharmacother. 2021;141:111871. https://doi.org/10.1016/j.biopha.2021.111871
Davizon-Castillo P, Di Paola J. Tamoxifen Suppresses Platelet Activation-Supported Angiogenesis and Metastasis. Arterioscler Thromb Vasc Biol. 2017;37(4):611–2. https://doi.org/10.1161/ATVBAHA.117.309105.
留言 (0)